Compare Avient Corporation (AVNT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Moderna, Inc. — how do they compare? Avient Corporation trades at $45.2 (market cap $4.17B), while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 5.8× Avient Corporation's market cap, and Avient Corporation pays a 2.42% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AVNT | MRNA | |
|---|---|---|
Market Cap | $4.17B | $24.18B |
Sector | Technology | Health |
52-Week High | $45.69 | $81.80 |
52-Week Low | $27.48 | $22.36 |
Enterprise Value | $5.62B | $20.33B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVNT trades at $45.33, down 0.7% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and raised full-year guidance. Revenue growth of 5.8% to $917 million reflects robust demand and operational efficiency. Analysts maintain a buy consensus with a $49.00 price target, citing momentum and value metrics.
Outlook is positive due to consistent earnings beats and dividend payments, but risks include high valuation (P/E 24.55) and potential margin pressure from input costs. Investors should monitor Q3 2026 results against the $0.79 EPS estimate for sustained growth confirmation.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
